Divi's Laboratories (DIVISLAB) Share Price & Analysis
Divi's Laboratories (DIVISLAB) — Drug Manufacturers - Specialty & Generic
Divi's Laboratories Key Fundamental Metrics
Executive Investment Overview & Business Profile
Divi's Laboratories commands a premium valuation with a P/E of 86.554016, supported by high market dominance and profitability expectations.
Divi's Laboratories is one of the premier companies in India's Healthcare sector. Currently trading at ₹8,349 with a market capitalization of ₹2.22 Lakh Cr, the company occupies a key position in the Indian equity market.
Investors evaluating Divi's Laboratories focus closely on its capital return metrics: Return on Equity (ROE) stands at N/A alongside operating margins of 36.66%. The company's earnings multiple of 86.554016 P/E provides a clear signal of market expectation relative to sector peers.
Company Profile & Information
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.